Last updated: May 2026 | Medical Disclaimer: This article is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always speak with a qualified healthcare professional before starting, stopping, or changing any medication.
| Key Takeaways |
|---|
| ✓ Tirzepatide activates two gut hormones simultaneously (GLP-1 and GIP), making it the only approved dual incretin agonist for type 2 diabetes and weight management. |
| ✓ In the SURMOUNT-5 head-to-head trial, tirzepatide produced 20.2% average body weight loss versus 13.7% with semaglutide (Wegovy) over 72 weeks. |
| ✓ Most side effects are gastrointestinal, mild to moderate, and tend to decrease over time. Serious risks, including thyroid C-cell tumors (from animal studies) and pancreatitis, require screening before starting treatment. |
You have probably heard of Ozempic. But there is a newer, clinically more potent option that is reshaping how doctors and patients think about metabolic health.
This guide breaks down what tirzepatide is, how it works, how it compares to semaglutide, and what the current evidence says about its long-term safety.
1. What Exactly Is Tirzepatide, and Why Is Everyone Talking About It?
Tirzepatide is a once-weekly injectable medication developed by Eli Lilly. It is sold under the brand name Mounjaro for type 2 diabetes management and as Zepbound for chronic weight management.
In India, the Central Drugs Standard Control Organisation (CDSCO) has approved Mounjaro for type 2 diabetes treatment, with Eli Lilly targeting a market launch in the country.
What sets tirzepatide apart from every other medication in its class is its dual mechanism. It activates two separate hormone receptors in the body: the GLP-1 receptor (glucagon-like peptide-1) and the GIP receptor (glucose-dependent insulinotropic polypeptide). No other approved medication does both simultaneously.
Drugs like semaglutide (Ozempic, Wegovy) only target the GLP-1 receptor. Tirzepatide targets both, which is why researchers and clinicians have taken to calling it a ‘twincretin.’
| Brand Name | Approved Indication |
| Mounjaro (tirzepatide) | Type 2 diabetes management (with diet and exercise) |
| Zepbound (tirzepatide) | Chronic weight management; moderate-to-severe obstructive sleep apnea |
The U.S. Food and Drug Administration (FDA) first approved tirzepatide as Mounjaro in May 2022 for type 2 diabetes. The obesity indication followed in November 2023 under the Zepbound brand name.
Both brands contain the identical active molecule at the same doses. The distinction is regulatory and commercial, not pharmacological.
2. How Does Tirzepatide Work? The Dual-Receptor Science Explained
To understand what makes tirzepatide different, it helps to understand two gut hormones that play a central role in how the body manages blood sugar and appetite.
GLP-1: The appetite-suppressing hormone
GLP-1 is released from the small intestine after eating. It stimulates the pancreas to release insulin, tells the liver to reduce glucose production, slows how quickly the stomach empties, and signals the brain to reduce appetite. Semaglutide and other GLP-1 receptor agonists mimic this hormone.
GIP: The underestimated partner
GIP is released earlier in the digestive process. Historically, it was considered less useful in people with type 2 diabetes because its ability to stimulate insulin appeared blunted.
More recent research, however, has shown that GIP plays an important role in fat tissue metabolism, insulin sensitivity, and potentially how the body responds to GLP-1 itself.
A key finding from pharmacological research is that when GIP and GLP-1 receptors are activated together, the combined metabolic effect is greater than either hormone alone. This synergy is the core pharmacological rationale for tirzepatide.
How the molecule is designed
Chemically, tirzepatide is a 39-amino-acid synthetic peptide based on the native GIP sequence. It carries a fatty acid chain that extends its half-life to approximately five days, which is what allows once-weekly dosing.
Pharmacological studies have confirmed that tirzepatide engages the GIP receptor more heavily than the GLP-1 receptor, while still activating both.
At the GLP-1 receptor specifically, it exhibits ‘biased agonism‘ that appears to enhance insulin secretion without the same degree of receptor desensitisation seen with pure GLP-1 agonists.
The practical result: tirzepatide triggers multiple metabolic pathways simultaneously, including improved insulin secretion, reduced glucagon release, slower gastric emptying, appetite suppression, and improved fat tissue function.
3. What Did the Clinical Trials Actually Show?
Tirzepatide has been tested across two major Phase 3 clinical trial programmes: SURPASS (for type 2 diabetes) and SURMOUNT (for weight management). Together, these programmes involved over 13,000 participants.
The SURMOUNT-1 trial: Weight loss without diabetes
SURMOUNT-1 enrolled 2,539 adults with obesity or overweight (without type 2 diabetes) and randomised them to tirzepatide at 5 mg, 10 mg, or 15 mg once weekly, or a placebo. The trial ran for 72 weeks. Results showed mean body weight reductions of 15.0%, 19.5%, and 20.9% for the three doses respectively, compared to 3.1% with placebo.
The SURMOUNT-5 trial: Head-to-head against semaglutide
This is the study most relevant to anyone comparing tirzepatide against Wegovy. SURMOUNT-5 was a Phase 3b randomised controlled trial that enrolled 751 adults with obesity or overweight (without type 2 diabetes) and directly compared tirzepatide against semaglutide 2.4 mg for 72 weeks. The results, published in The New England Journal of Medicine in 2025, showed:
| Outcome Measure | Tirzepatide | Semaglutide (Wegovy) |
| Mean weight loss | 20.2% | 13.7% |
| Mean weight lost (absolute) | 22.8 kg | 15.0 kg |
| Waist circumference reduction | 18.4 cm | 13.0 cm |
| Achieved >=10% weight loss | 81.6% | 60.5% |
| Achieved >=15% weight loss | 64.6% | 40.1% |
| Achieved >=20% weight loss | 48.4% | 27.3% |
| Achieved >=25% weight loss | 31.6% | 16.1% |
Tirzepatide delivered approximately 47% greater relative weight loss than semaglutide and was superior on the primary endpoint and all five key secondary endpoints. Both groups received lifestyle support as part of the trial protocol.
It is important to note that SURMOUNT-5 was open-label (participants knew which drug they were receiving) and was conducted primarily in the United States. These factors may influence interpretation, and individual responses will always vary.
4. How Is Tirzepatide Dosed and Administered?
Tirzepatide is administered as a subcutaneous injection once a week. It may be injected into the abdomen, thigh, or upper arm, with injection sites rotated with each dose. For a step-by-step walkthrough of how to inject tirzepatide safely at home, including site rotation and pen handling, see the dedicated guide.
The drug is available in pre-filled single-dose pens, multi-dose KwikPens, and single-dose vials.
The FDA-approved dosing schedule starts low and increases gradually. This titration approach is specifically designed to minimise gastrointestinal side effects during the body’s adjustment period.
| Dose Phase | Weekly Dose |
| Starting dose (weeks 1-4) | 2.5 mg once weekly |
| First escalation (weeks 5-8+) | 5.0 mg once weekly |
| Subsequent escalations (every 4+ weeks) | +2.5 mg increments as tolerated |
| Maximum approved maintenance dose | 15 mg once weekly |
The 2.5 mg starting dose is not a therapeutic dose. It is a tolerable step. Maintenance doses are typically 5 mg, 10 mg, or 15 mg depending on clinical response and side-effect tolerance. Not every patient needs to reach 15 mg.
If a dose is missed, it may be administered within four days (96 hours) of the scheduled date. If more than four days have passed, the missed dose should be skipped and the next regular dose taken on schedule.
Tirzepatide should be stored refrigerated at 2 to 8 degrees Celsius. If needed, individual pens may be kept at room temperature (up to 30 degrees Celsius) for up to 21 days.
5. What Are the Side Effects? Here Is What the Data Actually Says
The most common side effects of tirzepatide are gastrointestinal in nature. They typically appear during dose escalation and tend to reduce over time as the body adjusts.
Common gastrointestinal side effects (dose-dependent)
| Side Effect | Approx. Incidence at 5 mg | Approx. Incidence at 15 mg |
| Nausea | 13.3% | 24.1% |
| Diarrhoea | 13.2% | 20.8% |
| Vomiting | 5.7% | 14.0% |
| Constipation | Variable | Higher at 10 mg |
| Decreased appetite | Common | More frequent |
The incidence of new gastrointestinal events decreases over time across all dose groups. Drug discontinuation due to adverse events is highest at the 15 mg dose, affecting approximately 10% of patients in clinical trials.
Beyond GI: hair, energy, and body composition
Real-world reports highlight three additional concerns that are less prominent in trial tables but matter to patients: Mounjaro hair loss (typically telogen effluvium driven by rapid weight reduction), tirzepatide fatigue during dose escalation, and muscle loss on Mounjaro when calorie intake falls without adequate protein and resistance training.
Stomach discomfort and pain: What to watch for
Abdominal discomfort is reported commonly and is generally mild to moderate. Severe, persistent abdominal pain radiating to the back may be a signal of pancreatitis and requires immediate medical attention.
This is not a common occurrence in clinical trials, but it is a recognised warning in the prescribing information.
Nausea: How long does it last?
Nausea typically peaks in the first one to two weeks after each new dose level and tends to improve within two to four weeks of remaining at the same dose.
Eating smaller, lower-fat meals and avoiding lying down after eating can help reduce nausea during the adjustment period.
6. Is Tirzepatide Safe Long Term? What Current Evidence Shows
This is the question patients and clinicians most frequently raise. The honest answer is that the current evidence base is substantial but not yet complete.
The longest randomised controlled trials run approximately 72 to 88 weeks. Post-marketing surveillance and longer-term observational data are still accumulating.
Here is what the available evidence currently shows across key areas of concern.
Thyroid: The black box warning
Both Mounjaro and Zepbound carry an FDA black box warning (the most serious level of safety warning) regarding thyroid C-cell tumours. For a fuller breakdown of the tirzepatide thyroid risk and what it means in human terms, see the dedicated explainer.
In two-year rat studies, tirzepatide caused dose-dependent and duration-dependent increases in thyroid C-cell adenomas and carcinomas. The relevance of this finding to humans is currently unknown.
No cases of medullary thyroid carcinoma have been reported in the SURMOUNT human trials, and malignancy rates were comparable between tirzepatide and placebo arms across SURMOUNT-1 through SURMOUNT-4.
Tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). A healthcare provider should screen for these conditions before starting treatment.
Pancreatitis: Low incidence, but a listed risk
Acute tirzepatide pancreatitis carries an incidence of approximately 0.32 to 0.39% in real-world pharmacovigilance data. A meta-analysis of 9 clinical trials found no statistically significant increase in pancreatitis risk with tirzepatide versus controls (RR 1.46, 95% CI 0.59 to 3.61).
Tirzepatide has not been specifically studied in patients with a history of pancreatitis. Anyone with a history of pancreatitis or high-risk conditions such as biliary tract disease or severe hypertriglyceridaemia should discuss this carefully with a doctor before starting treatment.
Cardiovascular safety
The SURPASS-CVOT trial (NCT04255433) enrolled over 13,000 patients with type 2 diabetes and established cardiovascular disease to assess cardiovascular safety.
Post-hoc analyses of this trial presented at the American Heart Association in 2025 show tirzepatide was non-inferior to dulaglutide (a GLP-1 agonist) for major adverse cardiovascular events.
The SURMOUNT-MMO trial, currently enrolling more than 15,000 participants with obesity and high cardiovascular risk, is designed to directly measure tirzepatide’s effect on cardiovascular morbidity and mortality, with expected completion in October 2027.
Kidney safety
Current evidence from the SURPASS clinical trials suggests tirzepatide may benefit kidney function rather than harm it.
A pooled post-hoc analysis of the SURPASS-1 through SURPASS-5 trials (published in Diabetes Care, 2025) found tirzepatide was dose-dependently associated with reduced urine albumin-to-creatinine ratio (UACR), a marker of kidney stress.
Post-hoc data from SURPASS-CVOT presented at Kidney Week 2025 showed that in patients with very high-risk chronic kidney disease, eGFR declined at -3.0 vs. -7.2 mL/min per 1.73m2 with tirzepatide versus dulaglutide over 36 months, a statistically significant difference favouring tirzepatide.
A comparative FAERS pharmacovigilance study (PMC, 2025) found a lower reporting frequency for acute kidney injury with tirzepatide compared to semaglutide (ROR 0.44, 95% CI 0.38 to 0.50).
No dose adjustment is required for patients with impaired renal function, though renal function should be monitored during dose escalation if significant gastrointestinal side effects lead to dehydration.
What is not yet known
Long-term safety data beyond 72 to 88 weeks is limited. The SURMOUNT-MMO and SURPASS-CVOT results, expected from 2025 to 2027, will add meaningfully to the evidence.
Weight gain after stopping tirzepatide is also documented. The SURMOUNT-4 extension trial found approximately 14% weight regain over 52 weeks after discontinuation, underscoring that tirzepatide, like other GLP-1-class drugs, appears to require continued use to maintain its effects.
7. Tirzepatide vs. Semaglutide: How Do They Actually Compare?
This is one of the most searched questions in the metabolic health space. Here is a structured, evidence-based comparison.
| Parameter | Tirzepatide (Mounjaro / Zepbound) | Semaglutide (Ozempic / Wegovy) |
| Mechanism | Dual GLP-1 + GIP receptor agonist | GLP-1 receptor agonist only |
| Mean weight loss (72 weeks) | 20.2% (SURMOUNT-5) | 13.7% (SURMOUNT-5) |
| Peak weight loss in monotherapy trial | Up to 22.5% (SURMOUNT-1, 15 mg) | Up to 14.9% (STEP 1, 2.4 mg) |
| Approved for type 2 diabetes | Yes (Mounjaro) | Yes (Ozempic) |
| Approved for weight management | Yes (Zepbound) | Yes (Wegovy) |
| Approved for sleep apnea | Yes (Zepbound) | No |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection (Wegovy/Ozempic); once-daily oral tablet (Rybelsus) |
| Dosing range | 2.5 mg to 15 mg weekly | 0.25 mg to 2.4 mg weekly (injectable) |
| Common side effects | Nausea, diarrhoea, vomiting, constipation | Nausea, diarrhoea, vomiting, constipation |
| India availability (2025-26) | Mounjaro approved by CDSCO (diabetes); Zepbound under review | Ozempic available; Wegovy launch planned 2026 |
It is worth noting that the higher weight loss with tirzepatide may partly reflect the additive effects of GIP receptor activation. The GIP receptor appears to have effects on fat tissue metabolism and insulin sensitivity that complement GLP-1 receptor signalling.
Neither drug is universally ‘better’ for every patient. Individual response, tolerability, existing medical conditions, and access all matter.
| Bottom Line |
| Tirzepatide is a dual GLP-1 and GIP receptor agonist that has demonstrated greater weight loss than semaglutide in a head-to-head clinical trial. In the SURMOUNT-5 study, it produced an average of 20.2% body weight reduction over 72 weeks, versus 13.7% with semaglutide. |
| Most side effects are gastrointestinal, peak during dose escalation, and tend to improve with time. Serious risks require careful screening by a qualified doctor before starting treatment. |
| Long-term cardiovascular and renal data continue to accumulate, with large outcomes trials expected to report by 2025 to 2027. Tirzepatide should only be started under medical supervision and used alongside a reduced-calorie diet and increased physical activity. |
Frequently Asked Questions
What is tirzepatide and how is it different from semaglutide?
Tirzepatide is a once-weekly injectable medication that activates two gut hormone receptors simultaneously: GLP-1 and GIP. Semaglutide activates only the GLP-1 receptor.
This dual mechanism may explain why tirzepatide has consistently produced greater weight loss in clinical trials, including a 47% greater relative weight reduction versus semaglutide in the head-to-head SURMOUNT-5 trial.
What are the brand names for tirzepatide in India?
Tirzepatide is marketed as Mounjaro (for type 2 diabetes) and Zepbound (for weight management and sleep apnea) by Eli Lilly.
In India, Mounjaro has received approval from the CDSCO for the diabetes indication, with a planned market launch.
Zepbound’s approval in India is still pending as of mid-2026. Speak with an endocrinologist for current availability and prescription guidance in your region.
Is tirzepatide approved for weight loss or only diabetes?
Both. Tirzepatide is FDA-approved in the United States as Mounjaro for type 2 diabetes (approved May 2022) and as Zepbound for chronic weight management (approved November 2023) and moderate-to-severe obstructive sleep apnea (approved December 2024).
In India, only the diabetes indication (Mounjaro) has regulatory approval at the time of this writing.
How does tirzepatide work as a dual GLP-1 and GIP agonist?
Tirzepatide mimics two gut hormones that are naturally released after eating. GLP-1 stimulates insulin secretion, reduces glucagon, slows gastric emptying, and suppresses appetite.
GIP enhances glucose-stimulated insulin secretion and may improve insulin sensitivity in fat tissue.
When both receptors are activated together, the combined metabolic effect appears greater than activating either receptor alone, producing stronger blood sugar control and more significant weight reduction.
Is tirzepatide safe to take long term?
Current data from trials up to 72 to 88 weeks suggest tirzepatide is well-tolerated, with gastrointestinal side effects being the most common concern.
A black box warning exists for thyroid C-cell tumours based on animal studies; this risk has not been confirmed in humans, but the drug is contraindicated for people with personal or family history of medullary thyroid carcinoma.
Larger outcome trials (SURMOUNT-MMO, SURPASS-CVOT) are expected to provide more definitive long-term safety data by 2025 to 2027. Any decision about long-term use should involve a qualified healthcare provider.
What are the potential long-term risks of tirzepatide?
The currently identified long-term risks include: thyroid C-cell tumours (documented in rodent studies; human relevance uncertain), acute pancreatitis (rare, approximately 0.32 to 0.39% incidence), gallbladder disease (reported in the SURMOUNT trials at approximately 1.1%), and weight regain after stopping the medication.
Emerging data on kidney and cardiovascular outcomes are generally positive, but multi-year evidence beyond 88 weeks remains limited as of 2026.
Is tirzepatide safe for kidneys and liver long term?
Available evidence suggests tirzepatide may be beneficial rather than harmful for kidney function.
Pooled analysis from the SURPASS trials shows dose-dependent reductions in urinary albumin excretion, a marker of kidney stress. eGFR decline was significantly slower with tirzepatide versus dulaglutide in patients with high-risk chronic kidney disease.
For liver health, tirzepatide is being investigated in metabolic-associated fatty liver disease (MAFLD) with early data suggesting benefit. Definitive long-term liver and kidney outcome trials are ongoing.
Medical Disclaimer
This article is intended for general informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical consultation, diagnosis, or treatment. Individual responses to tirzepatide vary significantly. Always consult a qualified endocrinologist, diabetologist, or general physician before making any decisions regarding medication. If you are experiencing symptoms that concern you, seek medical attention promptly.
